好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

A Novel International Patient Registry in Myasthenia Gravis Linking Clinical and Patient-reported Outcomes Data: The Vitaccess Real MG (VRMG) Registry
Neuromuscular and Clinical Neurophysiology (EMG)
P6 - Poster Session 6 (11:45 AM-12:45 PM)
11-034

To design a global patient registry (“Vitaccess Real MG”) to optimally quantify the impacts of disease and treatment on patients living with myasthenia gravis (MG) using electronic medical record (EMR) and patient-reported outcome (PRO) data.

Myasthenia Gravis (MG) is a rare, chronic, autoimmune disease characterized by debilitating and fluctuating muscular weakness. There is no robust source for MG research combining PROs and clinical data, including symptoms, daily activities and quality of life.

Patients with a clinically-confirmed diagnosis of MG are recruited in the US and UK, with planned expansion to additional European countries in 2025/6. In all countries, recruitment can occur at clinical sites, with healthcare professionals contributing clinical data from patients’ medical records. In the US only, patients can also be recruited direct-to-patient or via their treating community neurologist; in both cases, clinical data are captured retrospectively via an electronic medical record aggregator. Clinical data – including medical history, treatment history, and adverse events – are captured on a six-monthly basis.

For all patients, clinical data are linked with PRO data – including: Myasthenia Gravis Activities of Daily Living; MG Symptoms PRO Fatigue Scale; NeuroQoL Fatigue Short Form; and Myasthenia Gravis Quality of Life 15-item Revised Scale. Patients contribute PRO data directly via the web-enabled VRMG platform on a monthly or bi-monthly basis, in order to track disease activity between clinic visits. Patients can opt in to receiving weekly text message prompts to capture MG symptom changes.

Direct-to-patient and community neurologist recruitment in the US were initiated in July 2024, and site recruitment in the US and UK were initiated on September and October 2024, respectively.    

By integrating digitally-captured clinical data and PROs, this novel registry aims to improve understanding of the symptoms and quality of life impact experienced by MG patients, in order to optimize future disease management.

Authors/Disclosures
Francesco Sacca, MD, FAAN (University Federico II)
PRESENTER
Dr. Sacca has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Alexion. Dr. Sacca has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Argenx. Dr. Sacca has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Lexeo. Dr. Sacca has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Biogen. Dr. Sacca has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genpharm. Dr. Sacca has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Sacca has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Medpharma. Dr. Sacca has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Madison Pharma. Dr. Sacca has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Zai Lab. Dr. Sacca has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Dianthus. Dr. Sacca has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Reata. Dr. Sacca has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sandoz. Dr. Sacca has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Neopharm Israel. Dr. Sacca has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Johnson&Johnson. Dr. Sacca has received personal compensation in the range of $500-$4,999 for serving as a Consultant for UCB. Dr. Sacca has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Astrazeneca. The institution of Dr. Sacca has received research support from AIFA. The institution of Dr. Sacca has received research support from FARA.
Fatemeh Amini, MScR Miss Amini has nothing to disclose.
Jack Lawrence Mr. Lawrence has received personal compensation for serving as an employee of Vitaccess. The institution of Mr. Lawrence has received research support from UCB.
Sally Vincent, MSc Miss Vincent has nothing to disclose.
Tsitsi Monera-Penduka, PhD Dr. Monera-Penduka has nothing to disclose.
Geraldine Hall, Bachelors Ms. Hall has received personal compensation for serving as an employee of Vitaccess. The institution of Ms. Hall has received research support from UCB.
Alasdair Fellows, MSc Mr. Fellows has nothing to disclose.
Mark Larkin, PhD Dr. Larkin has received personal compensation for serving as an employee of Vitaccess.
Anna Scowcroft (UCB) Anna Scowcroft has received personal compensation for serving as an employee of UCB. Anna Scowcroft has stock in UCB.
Raphaelle Beau Lejdstrom Raphaelle Beau Lejdstrom has received personal compensation for serving as an employee of UCB Frachim SA.
Natasa Savic (UCB) Mrs. Savic has nothing to disclose.
Saiju Jacob, MD, FAAN Dr. Jacob has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for ArgenX. Dr. Jacob has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for UCB Pharma. Dr. Jacob has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Regeneron Pharmaceuticals. Dr. Jacob has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion Pharmaceuticals. Dr. Jacob has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Janssen Pharmaceuticals. Dr. Jacob has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Merck. Dr. Jacob has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Jacob has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for UCB Pharmaceuticals. Dr. Jacob has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Terumo BCT. Dr. Jacob has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Argen X. Dr. Jacob has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Merck.
Ali A. Habib, MD (University of California, Irvine) Dr. Habib has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Alexion. Dr. Habib has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for argenx. Dr. Habib has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Immunovant. Dr. Habib has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for UCB. Dr. Habib has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Pfizer. Dr. Habib has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Genentech/Roche. Dr. Habib has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for NMD Pharma. Dr. Habib has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Horizon/ Amgen. Dr. Habib has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Grifols. Dr. Habib has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Kyverna. Dr. Habib has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Jansen/Johnson & Johnson. Dr. Habib has received personal compensation in the range of $500-$4,999 for serving as a Consultant for EMDSerono/Merck. Dr. Habib has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for NIH/NINDS. Dr. Habib has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Immunis Biomedical. Dr. Habib has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Hoffman-La Roche. Dr. Habib has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. Dr. Habib has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Alexion. Dr. Habib has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for argenx. Dr. Habib has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for UCB. Dr. Habib has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Jansen/Joohnson & Johnson. The institution of Dr. Habib has received research support from Alexion. The institution of Dr. Habib has received research support from Horizon/Amgen. The institution of Dr. Habib has received research support from Immunovant. The institution of Dr. Habib has received research support from UCB. The institution of Dr. Habib has received research support from argenx. The institution of Dr. Habib has received research support from CabalettaBio. The institution of Dr. Habib has received research support from Regeneron. The institution of Dr. Habib has received research support from Arcellx. The institution of Dr. Habib has received research support from Novartis. The institution of Dr. Habib has received research support from EMDSerono/Merck. The institution of Dr. Habib has received research support from Cour Pharmaceuticals.
Amanda Hayes, Patient expert Mrs. Hayes has nothing to disclose.